Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Ablynx
company
About
Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.
- 251 - 500
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $30M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$80M
Ablynx has raised a total of
$80M
in funding over 2 rounds. Their latest funding was raised on
Aug 23, 2006 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 23, 2006 | Series C | $50M | 1 | — | — | Detail |
| Apr 6, 2004 | Series B | $30M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Ablynx is funded by 1 investors.
Biotech Fund Flanders
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Biotech Fund Flanders
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
